Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Phosphoinositides and PIPs01:42

Phosphoinositides and PIPs

Phosphoinositides are a group of phospholipids containing a glycerol backbone with two fatty acid chains and a phosphate attached to a myoinositol sugar ring. The inositol head group extends into the cytoplasm, where it is modified by adding phosphate groups to form phosphatidylinositol phosphates or PIPs.
Different phosphoinositides are synthesized and recruited on the cytosolic face of the plasma membrane. The localization of specific phosphoinositides concentrated in separate membrane...
IP3/DAG Signaling Pathway01:11

IP3/DAG Signaling Pathway

Membrane lipids such as phosphatidylinositol (PI) are precursors for several membrane-bound and soluble second messengers. Specific kinases phosphorylate PI and produce phosphorylated inositol phospholipids. One such inositol phospholipids are the  phosphatidylinositol-4,5 bisphosphate [PI(4,5)P2], present in the inner half of the lipid bilayer. Upon ligand binding, GPCR stimulates Gq proteins to turn on phospholipase Cꞵ. Activated phospholipase Cꞵ cleaves PI(4,5)P2 and produces two-second...
Amplifying Signals via Enzymatic Cascade01:22

Amplifying Signals via Enzymatic Cascade

When a ligand binds to a cell-surface receptor, the receptor's intracellular domain changes shape, which may either activate its enzyme function or allow its binding to other molecules. The initial signal is amplified by most signal transduction pathways. This means that a single ligand molecule can activate multiple molecules of a downstream target. Proteins that relay a signal are most commonly phosphorylated at one or more sites, activating or inactivating the protein. Kinases catalyze the...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

KRAS Inhibitor Induced Cancer Cell Death Enhances Sensitivity to Immune-Mediated Bystander Killing of Drug-Resistant Subclones.

Cancer research·2026
Same author

Sensitizing Lung Cancer to Immunotherapy with a RAS(ON) Inhibitor Doublet.

Cancer discovery·2026
Same author

Nociceptive innervation limits tertiary lymphoid structures to promote lung cancer.

Cell·2026
Same author

A Roadmap to Transform Lung Cancer Outcomes: Priorities in Biology, Therapeutic Innovation, Early Detection, Prevention, and Interception.

Cancer discovery·2026
Same author

Retraction Note: Antibodies against endogenous retroviruses promote lung cancer immunotherapy.

Nature·2026
Same author

Covalent inhibitors of the PI3Kα RAS binding domain impair tumor growth driven by RAS and HER2.

Science (New York, N.Y.)·2025

Related Experiment Video

Updated: May 30, 2026

Identification of Inositol Phosphate or Phosphoinositide Interacting Proteins by Affinity Chromatography Coupled to Western Blot or Mass Spectrometry
08:07

Identification of Inositol Phosphate or Phosphoinositide Interacting Proteins by Affinity Chromatography Coupled to Western Blot or Mass Spectrometry

Published on: July 26, 2019

RAS Interaction with PI3K: More Than Just Another Effector Pathway.

Esther Castellano1, Julian Downward

  • 1Signal Transduction Laboratory, Cancer Research UK London Research Institute, London, UK.

Genes & Cancer
|July 23, 2011
PubMed
Summary

RAS proteins are key in cancer, impacting cell functions via pathways like Phosphatidylinositol 3-kinase (PI3K). Blocking RAS-PI3K interaction in mice significantly reduced tumor development, suggesting therapeutic potential.

Keywords:
PI3-kinaseRaslung cancerlymphangiogenesis

More Related Videos

Co-immunoprecipitation Assay for Studying Functional Interactions Between Receptors and Enzymes
09:40

Co-immunoprecipitation Assay for Studying Functional Interactions Between Receptors and Enzymes

Published on: September 28, 2018

Mapping Dysfunctional Protein-Protein Interactions in Disease
09:39

Mapping Dysfunctional Protein-Protein Interactions in Disease

Published on: October 24, 2025

Related Experiment Videos

Last Updated: May 30, 2026

Identification of Inositol Phosphate or Phosphoinositide Interacting Proteins by Affinity Chromatography Coupled to Western Blot or Mass Spectrometry
08:07

Identification of Inositol Phosphate or Phosphoinositide Interacting Proteins by Affinity Chromatography Coupled to Western Blot or Mass Spectrometry

Published on: July 26, 2019

Co-immunoprecipitation Assay for Studying Functional Interactions Between Receptors and Enzymes
09:40

Co-immunoprecipitation Assay for Studying Functional Interactions Between Receptors and Enzymes

Published on: September 28, 2018

Mapping Dysfunctional Protein-Protein Interactions in Disease
09:39

Mapping Dysfunctional Protein-Protein Interactions in Disease

Published on: October 24, 2025

Area of Science:

  • Oncology
  • Molecular Biology
  • Cell Signaling

Background:

  • RAS proteins, small GTPases, are frequently mutated in human cancers (approx. 25%).
  • RAS signaling regulates critical cellular processes including proliferation, differentiation, apoptosis, and senescence.
  • Phosphatidylinositol 3-kinase (PI3K) is a major RAS effector pathway involved in cell growth, survival, and metabolism, with significant implications in tumorigenesis.

Purpose of the Study:

  • To review the current understanding of how RAS regulates PI3K.
  • To highlight the role of the RAS-PI3K pathway in oncogenesis.
  • To discuss the therapeutic implications of targeting this pathway.

Main Methods:

  • Literature review of RAS and PI3K signaling.
  • Analysis of studies on RAS-induced transformation and tumorigenesis.
  • Examination of PI3K inhibitors and combination therapies.

Main Results:

  • PI3K is essential for RAS-induced cellular transformation in vitro.
  • Mice with PI3K mutations preventing RAS interaction show resistance to KRAS- and HRAS-driven cancers.
  • These mice also exhibit delayed lymphatic vasculature development.
  • Numerous PI3K inhibitors are in clinical trials, but pathway complexity poses prediction challenges.

Conclusions:

  • The RAS-PI3K interaction is a critical node in cancer development.
  • Targeting PI3K, potentially in combination with other RAS-regulated pathways like RAF/MEK/ERK, shows promise for cancer therapy.
  • Further research is needed to overcome the complexities of PI3K pathway inhibition for effective clinical application.